Dividend Policy - Yunnan Baiyao emphasizes sustainable and reasonable returns to investors, with a 2023 dividend plan of CNY 20.77 per 10 shares, totaling CNY 3.706 billion, which accounts for 90.53% of the 2023 net profit attributable to shareholders [2] - The company has consistently paid dividends for 31 years since its listing in 1993, with cumulative cash dividends exceeding CNY 24.4 billion [2] Pharmaceutical Business Performance - In 2023, the pharmaceutical segment generated revenue of CNY 6.481 billion, marking an 8.16% year-on-year increase [3] - Key products showed strong growth, with Yunnan Baiyao aerosol sales exceeding CNY 1.7 billion, up 15.27% [3] - Other significant products include Yunnan Baiyao ointment (over CNY 900 million), Yunnan Baiyao capsules (over CNY 600 million), and several traditional Chinese medicine products achieving over CNY 100 million in sales [4] Oral Care Market - Yunnan Baiyao toothpaste held a 24.60% market share in 2023, maintaining the top position [5] - During the "Double 11" shopping festival, the official flagship store for Yunnan Baiyao toothpaste achieved over CNY 100 million in sales, becoming the first flagship store to do so with a single product [5] - The company employed a dual-channel strategy to enhance brand visibility, conducting over 14,700 promotional events across 1,465 cities [5] Research and Development Strategy - The company leverages its Central Research Institute to coordinate R&D across four centers, focusing on traditional Chinese medicine and innovative drug development [6] - Key R&D centers include Kunming (traditional medicine), Beijing (academic collaboration), Shanghai (innovative drugs), and Wuxi (medical devices) [6] Future Outlook - Yunnan Baiyao aims to position itself as a comprehensive health solution provider, focusing on pharmaceuticals, health, and medical distribution [7] - The company plans to strengthen its core competencies in traditional Chinese medicine and expand its market leadership while exploring new business growth opportunities [8] - A strategic investment capability and risk management system will be developed to support healthy and efficient growth in core and innovative businesses [8]

Financial Performance - In Q1 2024, the company achieved revenue of CNY 10.774 billion, a year-on-year increase of 2.49% [2] - The net profit attributable to shareholders was CNY 1.702 billion, up 12.12% year-on-year [2] - For the full year 2023, total revenue reached CNY 39.111 billion, an increase of 7.19% from CNY 36.488 billion in 2022 [2] - The net profit attributable to shareholders for 2023 was CNY 4.094 billion, a significant rise of 36.41% [2] - The basic earnings per share for 2023 was CNY 2.29, with a return on equity of 10.51% [2] Product Sales Performance - The sales revenue of the Yangyuanqing anti-hair loss products exceeded CNY 300 million in 2023, marking a 36% year-on-year growth [3] - During the "Double 11" shopping festival, Yangyuanqing ranked first in the Tmall national anti-hair loss category and achieved over CNY 100 million in sales on Douyin [3] Oral Care Market - In 2023, Yunnan Baiyao toothpaste held a 24.60% market share in the domestic market, maintaining the leading position [4] - The flagship store on Tmall achieved over CNY 100 million in sales, becoming the first toothpaste single product to reach this milestone [4] - The company conducted over 14,700 offline promotional activities, covering 1,465 cities [4] Dividend Policy - In 2023, Yunnan Baiyao's dividend plan was CNY 20.77 per 10 shares, totaling CNY 3.706 billion, which accounted for 90.53% of the net profit attributable to shareholders [5] - The company has consistently paid dividends for 31 years since its listing, with cumulative cash dividends exceeding CNY 24.4 billion [5]

Group 1: Investor Relations Activity - The meeting was categorized as a specific object survey [1] - Participants included investors from Huafu Securities Yunnan Branch [1] - The event took place on July 3, 2024, at the company's headquarters [1] Group 2: Company Overview - The main focus of the meeting was to understand the company's production and operational status [1] - The meeting was attended by representatives from the company, including securities affairs representative Li Mengjue and investor relations manager Yang Kexin [1]

Financial Performance - In Q1 2024, the company achieved a revenue of CNY 10.774 billion, a year-on-year increase of 2.49% [2] - The net profit attributable to shareholders was CNY 1.702 billion, up 12.12% year-on-year [2] - For the full year 2023, total revenue reached CNY 39.111 billion, an increase of 7.19% from CNY 36.488 billion in 2022 [2] - The net profit attributable to shareholders for 2023 was CNY 4.094 billion, a significant rise of 36.41% compared to CNY 3.001 billion in 2022 [2] - Basic earnings per share for 2023 were CNY 2.29, with a return on equity of 10.51%, up 2.64 percentage points year-on-year [2] Core Product Sales - The sales revenue of the Yunnan Baiyao aerosol exceeded CNY 1.7 billion, growing by 15.27% [3] - Other core products, including Yunnan Baiyao adhesive bandages and ointments, also reported sales over CNY 1 billion, with ointments exceeding CNY 900 million and capsules over CNY 600 million [3] - The company is focusing on enhancing its core competitiveness through collaborations with academic institutions and targeted marketing strategies [3] Online Marketing Strategies - In 2023, the health product division leveraged major online shopping events like "618" and "Double 11" to boost sales through partnerships with platforms like Tmall, JD.com, and Pinduoduo [4] - Creative live streaming on platforms such as Douyin was employed to expand online market share [4] - Brand exposure was enhanced through collaborations with popular IPs and content marketing initiatives [4] Future Outlook - The company aims to position itself as a comprehensive solution provider in the health sector, focusing on pharmaceuticals, health products, and medical distribution [5] - Plans include strengthening the core position of traditional Chinese medicine and expanding its market leadership [5] - The company will adopt a cautious approach to new business development while ensuring the healthy growth of core and innovative businesses [5]

Group 1: Investor Relations Activity - The meeting was categorized as a "telephone conference" [1] - Participants included representatives from Jianxin Fund and Guolian Securities [1] - The meeting took place on July 1, 2024, at the company's headquarters [1] Group 2: Company Overview - The main focus was to understand the company's production and operational status [1] - The meeting was attended by the board secretary and investor relations representatives [1]

Group 1: Investor Relations Activity - The meeting was categorized as a telephone survey [1] - Participants included representatives from招商基金 and 国联证券 [1] - The meeting took place on July 1, 2024, at the company headquarters [1] Group 2: Purpose of the Meeting - The main focus was to understand the company's production and operational status [1] - The meeting aimed to address relevant questions from investors [1] Group 3: Attendees - Company representatives included 李孟珏 (Securities Affairs Representative) and 杨可欣, 张昱 (Investor Relations Management) [1] - A total of 10 participants from various investment firms attended the meeting [1]

Sales Performance and Marketing Strategies - In 2023, Yunnan Baiyao toothpaste held a domestic market share of 24.60%, maintaining the top position in the market [2] - During the "Double 11" shopping festival, the health product division achieved multiple first-place rankings, with the Yunnan Baiyao Tmall flagship store surpassing 100 million in sales for the first time [2] - Over 1.47 million offline promotional activities were conducted, covering 1,465 cities [2] Financial Performance - The health product division reported a revenue of 6.422 billion yuan in 2023, reflecting a year-on-year growth of 6.50% [3] - The provincial pharmaceutical company achieved a revenue of 24.49 billion yuan in 2023, with a year-on-year increase of 5.63% [4] Operational Efficiency - The provincial pharmaceutical company improved its overall operational efficiency, with a 7.4% increase in order fulfillment rate and a 22% enhancement in order response speed [4] - The company implemented a refined service system, offering delivery options such as same-day and next-day delivery [4] Research and Development Plans - The company focuses on short-term, mid-term, and long-term R&D projects, emphasizing market-driven innovation and evidence-based medicine [5] - Short-term goals include secondary innovation of existing products and rapid development of drug-device combinations [5] - Long-term strategies involve the development of innovative drugs, particularly in traditional Chinese medicine and nuclear medicine [5]

Group 1: Business Strategy and Growth - The pharmaceutical business group aims to lead in the injury sector, expand its market presence, and establish a comprehensive operation in the Sanqi industry [2] - The group will deepen academic research and collaborate with various institutions to enhance existing products and explore potential new products [2] - The focus will also be on upstream supply and production coordination to achieve smart manufacturing and cost reduction [2] Group 2: Health Products Performance - The health products business group achieved a revenue of 6.422 billion CNY in 2023, marking a year-on-year growth of 6.50% [3] - Yunnan Baiyao toothpaste holds a 24.60% market share in the domestic market, maintaining its leading position [4] - The health products group recorded significant online sales during the "Double 11" shopping festival, with the flagship store surpassing 100 million CNY in sales for the first time [4] - The anti-hair loss product line, Yangyuanqing, saw a revenue increase of 36%, exceeding 300 million CNY [4] Group 3: Dividend Policy - Yunnan Baiyao's 2023 dividend plan includes a payout of 20.77 CNY per 10 shares, totaling 3.706 billion CNY, which represents 90.53% of the net profit attributable to shareholders [6] - The company has consistently paid dividends for 31 years since its listing, with cumulative cash dividends exceeding 24.4 billion CNY [6] Group 4: R&D Progress in Nuclear Medicine - In 2023, the company made significant advancements in its nuclear medicine pipeline, receiving approval for clinical trials of the INR101 injection [7] - The INR102 project for prostate cancer treatment has completed preliminary studies and initiated pharmaceutical research [7]

Group 1: Investor Relations Activity - The investor relations activity was categorized as a phone survey [1] - Participants included representatives from E Fund Management [1] - The meeting took place on June 28, 2024, at the company's headquarters [1] Group 2: Meeting Purpose - The main purpose of the meeting was to understand the company's production and operational status [1] - The meeting involved discussions with the company's securities affairs representative and investor relations management [1]

具体内容详见公司同日在巨潮资讯网（网址：http://www.cninfo.com.cn） 披露的公告《关于引进 KA-1641 项目的公告》（公告编号：2024-39）。 股票代码：000538 股票简称：云南白药 公告编号：2024-38 云南白药集团股份有限公司 第十届董事会 2024 年第七次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 云南白药集团股份有限公司（以下简称"公司"或"云南白药"）第十 届董事会 2024 年第七次会议（以下简称"会议"）于 2024 年 6 月 27 日在 公司总部四楼会议室以现场结合通讯表决的方式召开，本次会议通知于 2024 年 6 月 21 日以书面、邮件或传真方式发出，应出席董事 11 名，实际 出席董事 11 名（其中董事李泓燊先生以通讯表决方式出席会议，独立董事 刘国恩先生、戴扬先生、何勇先生以视频方式出席会议）。本次会议的召集、 召开程序符合《中华人民共和国公司法》《公司章程》的相关规定，会议合 法有效。会议由公司董事长张文学先生主持，与会董事经充分讨论，会议审 议通过如下议案： 一、审议通 ...